![AbbVie Header](https://www.pharmacompass.com/image/flap/abbvie-header-w29-desktop-header-1gif-4289.gif)
![AbbVie Header](https://www.pharmacompass.com/image/flap/abbvie-header-w29-mobgif-81230.gif)
API Suppliers
US DMFs Filed
CEP/COS Certifications
0
JDMFs Filed
0
EU WC
0
Listed Suppliers
0
0
USA (Orange Book)
Europe
Canada
0
Australia
0
South Africa
0
Uploaded Dossiers
0
U.S. Medicaid
0
Annual Reports
0
0
https://www.globenewswire.com/news-release/2024/05/28/2889029/33485/en/Xenon-Pharmaceuticals-Presents-Data-from-Phase-2-X-NOVA-Clinical-Trial-of-Azetukalner-in-Major-Depressive-Disorder-at-the-American-Society-of-Clinical-Psychopharmacology-2024-Annua.html
https://www.globenewswire.com/news-release/2024/05/08/2877885/0/en/Polarean-s-Xenon-MRI-to-be-Featured-at-Upcoming-ATS-2024-Conference.html
https://www.globenewswire.com/news-release/2024/05/02/2874645/33485/en/Xenon-Pharmaceuticals-Announces-Conference-Call-and-Webcast-to-Discuss-First-Quarter-2024-Financial-Results-and-Provide-Corporate-Update.html
https://www.evaluate.com/vantage/articles/news/snippets/xenon-finally-finds-way-forward-epilepsy-win
https://www.globenewswire.com/news-release/2021/10/04/2307753/33485/en/Xenon-Pharmaceuticals-Announces-Positive-Topline-Results-from-Phase-2b-X-TOLE-Clinical-Trial-of-XEN1101-for-the-Treatment-of-Focal-Epilepsy.html
https://www.evaluate.com/vantage/articles/news/snippets/xenon-finally-finds-way-forward-epilepsy-win
https://www.globenewswire.com/news-release/2021/10/04/2307753/33485/en/Xenon-Pharmaceuticals-Announces-Positive-Topline-Results-from-Phase-2b-X-TOLE-Clinical-Trial-of-XEN1101-for-the-Treatment-of-Focal-Epilepsy.html
https://www.globenewswire.com/news-release/2021/07/13/2261989/33485/en/Xenon-Pharmaceuticals-to-Participate-at-the-William-Blair-Biotech-Focus-Conference-2021.html
https://www.prnewswire.com/news-releases/neurocrine-biosciences-and-xenon-pharmaceuticals-announce-agreement-to-develop-first-in-class-treatments-for-epilepsy-300967168.html
http://www.fiercebiotech.com/biotech/xenon-s-teva-partnered-pain-drug-flunks-another-test